Medtronic Acquires SPR for $650M to Bolster Pain Therapy Portfolio — Medtronic plc

Event summary

Medtronic completed the acquisition of SPR Therapeutics on July 16, 2026 for $650 million in cash.
The deal adds SPR's FDA-cleared SPRINT® PNS System to Medtronic’s pain therapy portfolio.
SPRINT® is a short-term, minimally invasive peripheral nerve stimulation (PNS) therapy for chronic and acute pain.
Clinical data shows 60% of patients achieved ≥50% pain relief with the treatment.

The big picture

Medtronic’s acquisition of SPR strengthens its position in neuromodulation, a high-growth area within pain management. The deal aligns with the broader industry shift toward non-opioid, minimally invasive solutions for chronic and acute pain, addressing a market affecting nearly 50 million U.S. adults. Medtronic now holds one of the broadest pain therapy portfolios in the industry, reinforcing its leadership in healthcare technology.

What we're watching

Integration Challenges: How Medtronic will integrate SPR’s technology into its existing pain therapy portfolio and scale its reach.
Market Expansion: Whether the acquisition will accelerate adoption of non-opioid pain treatments in both chronic and acute care settings.
Financial Impact: The pace at which the deal becomes accretive to Medtronic’s earnings, given its expected minimal dilution in FY27.